Reversibility of cirrhosis in HIV/HBV coinfection

Antiviral Therapy

Volumn 12, Issue 2, 2007, Pages 279-283

  Mallet, Vincent O ^a,b,c   Dhalluin Venier, Valérie ^a,b   Verkarre, Virginie ^a,d   Correas, Jean Michel ^a,d   Chaix, Marie Laure ^a,d   Viard, Jean Paul ^d   Pol, Stanislas ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Hépatologie ^*  (France)

^c INSTITUT COCHIN   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DIDANOSINE; EFAVIRENZ; HEPATITIS B VACCINE; LAMIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ABDOMINAL RADIOGRAPHY; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; COMORBIDITY; ECHOGRAPHY; GASTROINTESTINAL ENDOSCOPY; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LABORATORY TEST; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ADENINE; ADULT; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; PHOSPHONIC ACIDS; PLATELET COUNT; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 34147149667     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808-816.
2. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
3. Schiff ER, Dienstag IL, Karayalcin S, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003; 38:818-826.
4. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124:105-117.
5. Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol 2004; 40:860-867.
6. Soyer MT, Ceballos R, Aldrete JS. Reversibility of severe hepatic damage caused by jejunoileal bypass after re-establishment of normal intestinal continuity. Surgery 1976; 79:601-604.
7. Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997; 127:981-985.
8. Powell LW, Kerr JF. Reversal of "cirrhosis" in idiopathic haemochromatosis following long-term intensive venesection therapy. Australas Ann Med 1970; 19:54-57.
9. Kaplan MM, DeLellis RA, Wolfe HJ. Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med 1997; 126:682-688.
10. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon-α 2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122:1303-1313.
11. Pol S, Carnot F, Nalpas B, et al. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol 2004; 35:107-112.
12. Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon α therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004; 126:1740-1749.
13. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2005; 44 Suppl 1:S65-S70.
14. Lacombe K, Gozlan J, Boelle PY, et al. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. AIDS 2005; 19:907-915.
15. ter Borg F, ten Kate FJ, Cuypers HT, et al. A survey of liver pathology in needle biopsies from HBsAg- and anti-HBe-positive individuals. J Clin Pathol 2000; 53:541-548.
16. Rousselet MC, Michalak S, Dupre F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41:257-264.
17. Adinolfi LE, Giordano MG, Andreana A, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001; 113:590-595.
18. Poynard T, Zoulim F, Ratziu V, et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005; 100:1970-1980.
19. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006; 44:S65-S70.
20. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44:47-55.
21. Marine-Barjoan E, Saint-Paul MC, Pradier C, et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS 2004; 18:2163-2170.
22. Pol S, Driss F, Michel ML, Nalpas B, Berthelot P, Brechot C. Specific vaccine therapy in chronic hepatitis B infection. Lancet 1994; 344:342.
23. Wen YM, Wu XH, Hu DC, Zhang QP, Guo SQ. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet 1995; 345:1575-1576.
24. Pol S, Couillin I, Michel ML, et al. Immunotherapy of chronic hepatitis B by anti HBV vaccine. Acta Gastroenterol Belg 1998; 61:228-233.
25. Pol S, Nalpas B, Driss F, et al. Efficacy and limitations of a specific immunotherapv in chronic hepatitis B. J Hepatol 2001; 34:917-921.
26. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995; 171:1411-1419.
27. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30:1302-1306.
28. Hammer SM. Clinical practice. Management of newly diagnosed HIV infection. N Engl J Med 2005; 353:1702-1710.
29. Nunez M, Soriano V. Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect Dis 2005; 5:374-382.
30. Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-α and lamivudine therapy have failed. J Infect Dis 2002; 186:1844-1847.
31. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003; 17:F7-F10.
32. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42:615-624.